FDA Expands Opioid Prescription REMS to IR Formulations

Drug Industry Daily
A A
Manufacturers of short-acting opioids will be required to offer the kind of doctor training in administering the medications that their extended-release counterparts have been directed to provide since 2012, FDA Commissioner Scott Gottlieb said.

To View This Article:

Login

Subscribe To Drug Industry Daily